Merrill stays neutral on Angiotech

Angiotech Pharmaceuticals Inc. retained its neutral rating by Merrill Lynch analyst Hari Sambasivam. A news release from Biosensors International said that Angiotech was not successful in obtaining an injunction in the court proceedings in the Netherlands. The press release by Biosensors also claimed that the Dutch court had ruled that Biosensors had not infringed on Angiotech's patents. Shares of the Vancouver, B.C., pharmaceutical company were down 30 cents, or 2.07%, at $14.20 on volume of 125,405 shares versus the three-month running average of 187,105 shares. (Toronto: ANP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.